Headaches during initial use Headaches represent the second most commonly reported side effect
A 2006 scientific review described the natural occurrence and biological activity of DSIP as unresolved and proposed that DSIP-like material might arise from a related or precursor-associated molecule
Because these peptides may work through different biological pathways, some healthcare providers use them together as part of a personalized recovery plan
Shi Y, Chen C, Wu X, et al
However, evidence on its efficacy is thin
Dosing checklist: literature search pilot doses (e.g., 10, 50, 100 g/kg in small animal models) select dose based on safety and endpoint response document rationale